Newest patents significantly strengthen S1 intellectual property position New York, NY – December 20, 2018 – S1 Biopharma, Inc. (S1) announced today that the European Patent Office has granted a European Patent for the Company’s proprietary dual-mechanistic therapy Lorexys™ for…
Read more ›